FY2025 · ended Dec 31, 2025 · Revenue $3.57M, +32.9% YoY · Filed Mar 19, 2026
Neuraxis, Inc. (NRXS) files with the SEC under industry code 3845, Electromedical & Electrotherapeutic Apparatus. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $3.6 million and a net loss of $7.8 million. Free cash flow was -$6.5 million. As of Jun 30, 2026 it held $8.3 million in cash and investments and $279,392 in total debt.
Revenue (TTM)
$5.32M
+65.2% vs year-ago TTM
Net income (TTM)
$-7.68M
-7.1% vs year-ago TTM
Operating cash flow (TTM)
$-5.62M
+9.7% vs year-ago TTM
Free cash flow (TTM)
$-5.63M
+9.9% vs year-ago TTM
EPS (TTM)
$-0.78
+26.2% vs year-ago TTM
Dividend per share
None
Shares outstanding
11.19M
+55.0% vs prior year
Net cash
$8.04M
as of Jun 30, 2026
Operating margin
-144.5%
FY 2026
Company profile
- Industry
- Electromedical & Electrotherapeutic Apparatus (SIC 3845)
- Listed as
- NRXS (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Carmel, IN
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1933567
Other Electromedical & Electrotherapeutic Apparatus companies
- Medtronic plc MDT
- LivaNova PLC LIVN
- Integer Holdings Corp ITGR
- Axogen, Inc. AXGN
- TransMedics Group, Inc. TMDX
- CONMED Corp CNMD
- Ceribell, Inc. CBLL
- InMode Ltd. INMD
All 31 Electromedical & Electrotherapeutic Apparatus companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
|---|---|---|---|
| Revenue | $3.6M | $2.7M | $2.5M |
| Operating income | -$7.8M | -$7.2M | -$6.7M |
| Net income | -$7.8M | -$8.2M | -$14.6M |
| Diluted EPS | -$0.95 | -$1.22 | -$4.50 |
| Operating cash flow | -$6.4M | -$6.1M | -$6.7M |
| Free cash flow | -$6.5M | -$6.1M | -$6.7M |
| Total assets | $6.4M | $4.8M | $509,498 |
| Total liabilities | $3.0M | $2.7M | $1.9M |
| Stockholders' equity | $3.4M | $2.1M | -$1.4M |
| Cash and investments | $5.0M | $3.7M | $78,560 |
| Total debt | $416,611 | $473,405 | $224,260 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Oct 14, 2026 | Oct 14, 2026 |
| 8-K |
Current report
Officer or director change, Other events
|
Aug 19, 2026 | Jul 24, 2026 |
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Other events
|
Jul 10, 2026 | Jul 9, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 12, 2026 | Jun 10, 2026 |
| 10-Q | Quarterly report | May 12, 2026 | Mar 31, 2026 |
All 193 Neuraxis, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.